Skip to content
  • My Accountmy account
  • Search
FLCCC | Front Line COVID-19 Critical Care Alliance
  • Treatment
    Protocols

    • Protocols

      Read about strategies to prevent and treat conditions like COVID-19, insulin resistance, RSV, long COVID, and more.

      Learn More
      Prevention

      Boost your immune system, clear your body of spike protein, and learn the benefits of intermittent fasting.

      • EAT WELL
      • I-PREVENT Vaccine Injury
      • See all Prevention Protocols
      Treatment

      At-home and hospital treatment plans for COVID, insulin resistance, sepsis, RSV and flu.

      • I-CARE Early At Home Treatment
      • I-CARE RSV and Flu Treatment
      • See all Treatment Protocols
      Recovery

      Approaches to managing symptoms from long COVID and long Vax.

      • I-RECOVER Post Vaccine Treatment
      • I-RECOVER Long Covid
      • See all Recovery Protocols
  • Medical
    Evidence
    • Reviews & Monographs

      In-depth academic pieces presenting original research, analysis, and evidence on complex conditions.

      Cancer Care
    • Studies

      A comprehensive listing of all research, studies, authors and sources cited in each FLCCC prevention and treatment protocol for COVID-19

      Learn More
    • Lectures

      Watch FLCCC doctors speak at international medical conferences, professional seminars and symposiums.

      Learn More
    • Senate Testimony

      Watch Dr. Pierre Kory testify before the U.S. Senate regarding FLCCC protocols to treat COVID-19.

      Learn More
  • COVID
    Resources

    • Wondering where to begin?

      Let us help you find what you’re looking for. We know COVID-19 can be overwhelming; click below to learn more about the resources available to you on this website.

      get started
      Patient Resources
      • Find a Provider
      • Find a Pharmacy
      • Tools & Guides
      • Testimonials
      • Hospital Guide
      Practitioner Resources
      • Efficacy of Ivermectin
      • Informed Consent
      • Nurses for FLCCC
      • Join the Alliance
      • Education on Demand
  • Education &
    Events

    • About the education portal

      FLCCC’s goal is to educate healthcare providers and empower patients with the tools and resources they need to take control of their own health.

      Events

      Our twice-yearly conferences bring top experts from a variety of fields together to learn, share, and network with each other.

      • Learn More
      Education on Demand

      Stream video lectures, download slide presentations, and get exclusive access to key facts, data, and references from FLCCC educational programs.

      • My Content
      • Explore Courses
  • News &
    Webinars
    • Latest Updates

      Stay up-to-date with the latest news from our fast-moving field.

      View
    • Blog

      Subscribe to our blog to read our weekly news capsule and be the first to receive the latest announcements from FLCCC.

      Read Now
    • Weekly Webinars

      Sign up for our webinars, every Wednesday at 7pm ET, offering the latest information on therapeutics and treatments and answering audience questions.

      Learn More
    • FLCCC in the News

      Read media coverage of FLCCC from around the world.

      View
  • About
    FLCCC

    • About the FLCCC

      Learn about the history of FLCCC, our mission and vision, and how you can get involved.

      learn more
      • Our Physicians
      • Our Partners
      • Advocacy
      • FAQ
      • Terms and Conditions
      • Impact Reports
      • Annual Reports
      • Support Us
      • Shop our Store
      • Connect with Us
  • Donate
  • Treatment Protocols
  • Find a Provider
  • Find a Pharmacy
  • Medical Evidence
    • Cancer Care
    • Studies
    • Lectures
    • Senate Testimony
  • COVID Resources
    • Get Started
    • Tools & Guides
    • Ivermectin
    • Hospital Guide
    • Nurses for FLCCC
    • Join The Alliance
  • Education & Events
    • Educational Conference
    • Education on Demand
    • My Content
  • News & Webinars
    • Latest Updates
    • FLCCC Blog
    • Weekly Webinars
    • FLCCC in the News
  • About The FLCCC
  • FAQ
  • Connect with Us
  • Donate
  • Cart
FLCCC | Front Line COVID-19 Critical Care Alliance
  • Treatment Protocols
  • Find a Provider
  • Find a Pharmacy
  • Medical Evidence
    • Cancer Care
    • Studies
    • Lectures
    • Senate Testimony
  • COVID Resources
    • Get Started
    • Tools & Guides
    • Ivermectin
    • Hospital Guide
    • Nurses for FLCCC
    • Join The Alliance
  • Education & Events
    • Educational Conference
    • Education on Demand
    • My Content
  • News & Webinars
    • Latest Updates
    • FLCCC Blog
    • Weekly Webinars
    • FLCCC in the News
  • About The FLCCC
  • FAQ
  • Connect with Us
  • Donate
  • Cart
Donate

References

Categories

I-CARE Early Covid (187) I-CARE Flu and RSV (36) I-PREVENT (153) I-RECOVER Long Covid (111) I-RECOVER Post-Vaccine (320) MATH+ (198)

Tags

ACE2 protein (10) acute respiratory distress syndrome (14) Alopecia (7) Anti-inflammatory (9) Antidepressants (9) Ascorbic Acid (12) autoantibodies (10) autophagy (24) Calcifediol (6) Cancer (9) Corticosteroids (9) COVID-19 (270) COVID-19 Vaccines (8) Curcumin (8) Cytokines (12) Depression (10) Famotidine (14) flavonoids (5) Glucocorticoids (7) Hydroxychloroquine (12) Hyperbaric Oxygen Therapy (9) Inflammation (14) ivermectin (47) long COVID (21) Mast Cells (8) Melatonin (20) Methylprednisolone (7) molnupiravir (5) N-Acetylcysteine (6) Non-Invasive Brain Stimulation (8) Omicron (7) Oxytocin (8) Pneumonia (8) quercetin (15) SARS-CoV-2 (72) SARS-CoV-2 mRNA Vaccines (7) Sepsis (18) spermidine (11) Spike Protein (10) Thiamine (7) Thrombosis (9) Tinnitus (12) Vitamin C (28) Vitamin D (10) Zinc (12)
  • Reference: Oral nirmatrelvir and severe COVID-19 outcomes during the Omicron surge.

    Published On: September 1, 2022

    Authors: Arbel R, Sagy YW, Hoshen M, Battat E, Lavie G, Sergienko R et al. PMID: 36001529 PMCID: PMC9454652 DOI: 10.1056/NEJMoa2204919 Abstract Background: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of [...]

    Categories: I-CARE Early Covid

    Tags: COVID-19, nirmatrelvir, Omicron

  • Reference: Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant

    Published On: April 5, 2022

    The Omicron SARS-CoV-2 variant is responsible for a major wave of COVID-19, with record case counts reflecting high transmissibility and escape from prior immunity. Defining the time course of Omicron viral proliferation and clearance is crucial to inform isolation protocols aiming to minimize disease spread.

    Categories:

    Tags: COVID-19, Omicron, SARS-CoV-2, viral infection

  • Reference: Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A danish cohort study

    Published On: December 22, 2021

    In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines. Our study provides evidence of protection against infection with the Omicron variant after completion of a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines; in particular, we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%) and 36.7% (95% CI: 69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively, in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%).

    Categories:

    Tags: BNT162b2, COVID-19, Delta, mRNA-1273, Omicron

  • Reference: Diminished neutralization responses towards SARS-CoV-2 Omicron Voc after mRNA or vector-based COVID-19 vaccinations

    Published On: December 21, 2021

    SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-induced protection. The novel variant of concern Omicron (B.1.1.529) has to date the largest number of amino acid alterations in its Spike protein. Thus, it may efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in convalescent and vaccinated individuals.

    Categories: I-RECOVER Post-Vaccine

    Tags: Omicron, SARS-CoV-2 variants, Spike Protein

  • Reference: Epidemiological characterization of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021

    Published On: December 16, 2021

    By 9 December 2021, 785 SARS-CoV-2 Omicron variant cases have been identified in Denmark. Most cases were fully (76%) or booster-vaccinated (7.1%); 34 (4.3%) had a previous SARS-CoV-2 infection. The majority of cases with available information reported symptoms (509/666; 76%) and most were infected in Denmark (588/644; 91%).

    Categories:

    Tags: COVID-19, Denmark, Epidemiology, Omicron, SARS-CoV-2

  • Reference: SARS-CoV-2 Omicron variant: Characteristics and prevention

    Published On: December 16, 2021

    Characteristics and treatment of Omicron variant of COVID-19.

    Categories:

    Tags: COVID-19, Omicron, SARS-CoV-2

  • Reference: The omicron variant is highly resistant against antibody-mediated neutralization- implications for control of the COVID-19 pandemic

    Published On: December 13, 2021

    The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike-protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by Sotrovimab.

    Categories:

    Tags: COVID-19, Omicron

FLCCC Logo with white letters
Support Us

We are a 100% donor-supported 501(c)(3) non-profit organization. Our work would not be possible without you! Help us expand our reach and share life-saving research.

Give Now
shop
Contact Us
Mailing Address

FLCCC Alliance
2001 L St. NW Suite 500
Washington, DC 20036

Media

[email protected]

Clinical Support

[email protected]

General

[email protected]

Shortcuts
  • About the FLCCC

  • Protocols

  • Providers

  • Physicians

  • Testimonials

  • Latest Updates

  • Newsletter Signup

Follow Us
FLCCC Logo with white letters